Globus Medical, Inc. stock performance trend indicates that the stock price has rallied 18.62% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 29.02% . Looking at the past 52 week period, the stock price is up at 21.84% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Globus Medical, Inc. has a positive value of 5.27 compared to overall market.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 69.2.
Globus Medical, Inc. (NYSE:GMED) has climbed 6.55% in the past week and advanced 5.43% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 6.3% and the outperformance has advanced to 4.23% for the last 4 weeks period.
Company shares have received an average consensus rating of Hold for the current week Globus Medical, Inc. (NYSE:GMED) : On Friday heightened volatility was witnessed in Globus Medical, Inc. (NYSE:GMED) which led to swings in the share price. The stock opened for trading at $27.97 and hit $29.23 on the upside , eventually ending the session at $29.12, with a gain of 4.26% or 1.19 points. The heightened volatility saw the trading volume jump to 1,391,028 shares. The 52-week high of the share price is $29.23 and the company has a market cap of $2,795 million. The 52-week low of the share price is at $19.25 .
Company has reported several Insider transactions to the SEC, on Aug 8, 2016, A Brett Murphy (Group President, Commerical Op) sold 107,692 shares at 23.38 per share price.On Jan 6, 2016, Robert Liptak (director) sold 15,300 shares at 27.50 per share price.On Jan 6, 2016, Kurt Wheeler (director) sold 15,300 shares at 27.50 per share price.
Globus Medical Inc Last issued its quarterly earnings results on Feb 27, 2017. The company reported $0.31 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $0.33. The company had revenue of $151.59 million for the quarter, compared to analysts expectations of $149.80 million. The companys revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.
Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Companys products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania.